Welcome to this week's episode of The Metabolic Exchange Podcast, where we're privileged to host part 2 of our conversation with Dr. Naim Alkhouri, one of the nation's leading experts in metabolic liver disease and NASH therapeutics.

Dr. Alkhouri brings exceptional credentials to our discussion, serving as Director of the Steatotic Liver Program at Northshore Gastroenterology, Director of Research at the Clinical Research Institute of Ohio, and Chief Academic Officer at Summit Clinical Research in San Antonio. With over 300 published works and extensive experience as a Principal Investigator on numerous global NASH clinical trials, Dr. Alkhouri joins Dr. Joe Galati and Dr. Mazen Noureddin for an in-depth conversation about the rapidly evolving treatment landscape for metabolic dysfunction-associated steatotic liver disease (MASLD).

Fatty liver disease has emerged as one of the most significant public health challenges of our time, affecting an estimated 25-30% of the global population. What was once considered a benign condition is now recognized as a progressive disease that can lead to cirrhosis, liver failure, and hepatocellular carcinoma. The recent nomenclature change from NAFLD to MASLD reflects our growing understanding of the metabolic underpinnings of this condition, with insulin resistance, obesity, and type 2 diabetes serving as key drivers. As the obesity epidemic continues to expand, MASLD has become the leading cause of liver disease worldwide and a primary indication for liver transplantation.

In today's episode, our expert panel explores the landmark FDA-approved therapies that are finally providing hope for patients with this condition, as well as the promising drugs currently in the development pipeline. Dr. Alkhouri's unique perspective, with his innovative research on biomarkers for diagnosis, and his current role in multiple pharmaceutical trials—offers listeners invaluable insights into where the field is headed. This timely discussion couldn't come at a better moment, as we stand at the threshold of a new era in treating metabolic liver disease.

#Efruxifermin #Lanifibranor #Retatrutide #Survodutide #Resmetirom #Semaglutide

Thank you for listening to The Metabolic Exchange! We value your feedback and would love to hear your ideas for future topics and guests.

For general inquiries, please email us at info@themetabolicmosaic.com.

To learn more about Dr. Joe Galati and his work, visit his website You can connect with Dr. Mazen Noureddin hear and learn more about his clinic research initiatives.

Your engagement helps us create content that matters to you, and we appreciate your continued support of the show.

Hosted on Acast. See acast.com/privacy for more information.

Welcome to this week's episode of The Metabolic Exchange Podcast, where we're privileged to host Dr. Naim Alkhouri, one of the nation's leading experts in metabolic liver disease and NASH therapeutics.

Dr. Alkhouri brings exceptional credentials to our discussion, serving as Director of the Steatotic Liver Program at Northshore Gastroenterology, Director of Research at the Clinical Research Institute of Ohio, and Chief Academic Officer at Summit Clinical Research in San Antonio. With over 300 published works and extensive experience as a Principal Investigator on numerous global NASH clinical trials, Dr. Alkhouri joins Dr. Joe Galati and Dr. Mazen Noureddin for an in-depth conversation about the rapidly evolving treatment landscape for metabolic dysfunction-associated steatotic liver disease (MASLD).

Fatty liver disease has emerged as one of the most significant public health challenges of our time, affecting an estimated 25-30% of the global population. What was once considered a benign condition is now recognized as a progressive disease that can lead to cirrhosis, liver failure, and hepatocellular carcinoma. The recent nomenclature change from NAFLD to MASLD reflects our growing understanding of the metabolic underpinnings of this condition, with insulin resistance, obesity, and type 2 diabetes serving as key drivers. As the obesity epidemic continues to expand, MASLD has become the leading cause of liver disease worldwide and a primary indication for liver transplantation.

In today's episode, our expert panel explores the landmark FDA-approved therapies that are finally providing hope for patients with this condition, as well as the promising drugs currently in the development pipeline. Dr. Alkhouri's unique perspective, with his innovative research on biomarkers for diagnosis, and his current role in multiple pharmaceutical trials—offers listeners invaluable insights into where the field is headed. This timely discussion couldn't come at a better moment, as we stand at the threshold of a new era in treating metabolic liver disease.

#Efruxifermin #Lanifibranor #Retatrutide #Survodutide #Resmetirom #Semaglutide

Thank you for listening to The Metabolic Exchange! We value your feedback and would love to hear your ideas for future topics and guests.

For general inquiries, please email us at info@themetabolicmosaic.com.

To learn more about Dr. Joe Galati and his work, visit his website You can connect with Dr. Mazen Noureddin hear and learn more about his clinic research initiatives.

Your engagement helps us create content that matters to you, and we appreciate your continued support of the show.

Hosted on Acast. See acast.com/privacy for more information.

Inaugural conversation with Dr. Joe Galati and Dr. Mazen Noureddin: a high-level, clinically focused primer on fatty liver disease (MASLD), metabolic syndrome, and why this constellation of conditions represents a growing public‑health threat.

Both Dr. Galati and Dr. Noureddin are experts in liver disease and clinical research, bringing clinical perspective and trial experience to the discussion.

Geared to clinicians, advanced practice providers, researchers, and trial designers, we unpack new terminology and diagnostic framing for fatty liver, summarize current FDA‑approved drug therapies and promising agents in the development pipeline, and explain how evolving treatments fit into clinical practice and trial design.

Drs. Galati and Noureddin map the multidisciplinary “mosaic” of care—awareness and prevention, screening and diagnostics, lifestyle and metabolic management, and targeted therapeutic interventions—illustrating practical approaches for integrating these components to improve patient outcomes.

Listen for actionable insights on diagnosis, treatment planning, and the future of MASLD research and therapeutics.

Thank you for listening to The Metabolic Exchange! We value your feedback and would love to hear your ideas for future topics and guests.

For general inquiries, please email us at info@themetabolicmosaic.com.

To learn more about Dr. Joe Galati and his work, visit his website You can connect with Dr. Mazen Noureddin hear and learn more about his clinic research initiatives.

Your engagement helps us create content that matters to you, and we appreciate your continued support of the show.

Hosted on Acast. See acast.com/privacy for more information.

Thank you for listening to The Metabolic Exchange! We value your feedback and would love to hear your ideas for future topics and guests.

For general inquiries, please email us at info@themetabolicmosaic.com.

To learn more about Dr. Joe Galati and his work, visit his website You can connect with Dr. Mazen Noureddin hear and learn more about his clinic research initiatives.

Your engagement helps us create content that matters to you, and we appreciate your continued support of the show.

Hosted on Acast. See acast.com/privacy for more information.